Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Issues Precaution for Gardasil on Syncope, Falls
February 15, 2012
- MSD Cautions against Syncope, Fall after Gardasil Vaccination
February 15, 2012
- Major Pharmacy Chains to Boost Efforts to Raise GE Dispensing Rates Despite Dissatisfaction with Revised Premiums
February 15, 2012
- Altheos Initiates PIIa Trial for ATS907 in the US: Asahi Kasei Pharma
February 14, 2012
- Sawai Wins Patent Lawsuit on Ebastine
February 14, 2012
- Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
- Otsuka HD Director Kimura Anticipates Seroquel Patent Expiry to Impact Abilify
February 14, 2012
- AnGes MG to Seek Return of ¥75 Million Patent Remuneration from Board Member Morishita
February 14, 2012
- Otsuka HD Files Application for Antituberculosis Drug Delamanid in Europe
February 13, 2012
- April-December Pharmaceutical Sales Up 4.1% Driven by Abilify: Otsuka HD
February 13, 2012
- Altheos Begins PIIa Trial for ATS907 in US: Asahi Kasei Pharma
February 13, 2012
- AnGes MG Announces Positive Results from Exploratory Trial of CIN Vaccine
February 13, 2012
- Nippon Kayaku to Make Largest-ever Investment in Pharma R&D, with Shift to Biosimilars
February 13, 2012
- Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
- Takeda Sets Up Development Center at China Subsidiary to Boost Development in Asia
February 10, 2012
- Eisai to Transfer Shares and Equity of its Pharmaceutical Machinery Business Subsidiaries
February 10, 2012
- Nomura Report Recommends Otsuka HD, DSP, Eisai Shares
February 10, 2012
- Mr Takeuchi of Astellas Stresses Importance of IP Strategies in Tie-ups with Bioventures
February 10, 2012
- Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
- Sales of Ethical Drugs Up 5.3% in December: Crecon Report
February 9, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…